Corcept Therapeutics (CORT) FY2016 results: revenue $81 million, up 61.7% on the year
Corcept Therapeutics Inc. (CORT) reported revenue of $81 million for fiscal 2016, the year ended 31 December 2016, up 61.7% on the year before. Net income was $8 million, and diluted earnings per share $0.07. The figures are the company's own, from the 10-K it filed with the SEC on 26 February 2019.
Revenue
$81 million
+61.7% on the year
FY2009FY2016
Operating margin
12.5%
-6.8% a year earlier
FY2009FY2016
Net income
$8 million
FY2009FY2016
Diluted EPS
$0.07
FY2009FY2016
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Revenue
81.3
50.3
26.6
+61.7%
Cost of revenue
2.1
1.4
0.9
+51.2%
Gross profit
79.3
48.9
25.7
+62.0%
Gross margin
97.5%
97.3%
96.7%
Research and development
23.8
15.4
18.4
+54.6%
Selling, general and administrative
45.2
36.9
34.9
+22.4%
Operating income
10.2
-3.4
-27.6
Operating margin
12.5%
-6.8%
-104.0%
Pre-tax income
8.1
-6.4
n/a
Income tax
0.0
0.0
0.0
Effective tax rate
0.0%
n/a
n/a
Net income
8.1
-6.4
-31.4
Net margin
10.0%
-12.7%
-118.2%
Diluted EPS
$0.07
-$0.06
-$0.31
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Operating cash flow
18.4
3.1
-27.4
+487.6%
Capital expenditure
0.2
0.0
0.2
+1,041.2%
Free cash flow
18.2
3.1
-27.6
+484.5%
Free cash flow margin
22.4%
6.2%
-103.8%
Cash from investing
-0.2
n/a
n/a
Cash from financing
-7.1
n/a
n/a
Depreciation and amortisation
0.1
0.2
0.1
-43.9%
Share-based compensation
7.1
6.0
5.2
+17.4%
Buybacks
0.0
n/a
n/a
Diluted shares, weighted
116m
107m
101m
+8.7%
Shares outstanding at period end
113m
110m
101m
+2.8%
Balance sheet
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Shareholders' equity
41.4
18.5
-3.4
+123.7%
Debt
14.7
27.5
33.9
-46.7%
Other liabilities
12.7
5.9
4.1
+115.0%
Total liabilities and equity
68.8
51.9
34.6
+32.4%
Fixed assets
0.2
0.1
0.2
+109.2%
Investments
0.0
n/a
n/a
Cash and equivalents
51.5
40.4
24.2
+27.5%
Receivables
9.9
6.2
3.3
+58.5%
Inventory
2.3
1.7
1.2
+38.5%
Other assets
4.8
3.5
5.6
+37.8%
Total assets
68.8
51.9
34.6
+32.4%
10-K for the year ended 31 December 2016, filed 26 February 2019: the filing.